Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.35 |
| ▸ | BCR | P11274 | 2/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSPO | P30536 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1203845 | 0.82 | TSHR (0.46) | ALDH1A1CYP3A4TSHRMAPK1TDP1 | |
| SCHEMBL15105430 | 0.80 | ALDH1A1 (0.42) | ALDH1A1CYP3A4CYP1A1CYP1B1ABL1 | |
| SCHEMBL6671376 | 0.79 | TSHR (0.44) | ALDH1A1CYP3A4TSHRMAPK1TDP1 | |
| SCHEMBL460134 | 0.78 | MAPT (0.48) | ALDH1A1TSHRMAPK1MAPTRXRA | |
| SCHEMBL458557 | 0.77 | ALDH1A1 (0.41) | ALDH1A1CYP3A4TSHRMAPK1TDP1 | |
| SCHEMBL459993 | 0.75 | MAOB (0.38) | ALDH1A1CYP3A4TSHRMAPK1TDP1 | |
| SCHEMBL12501 | 0.74 | ALDH1A1 (0.73) | ALDH1A1CYP3A4TSHRMAPK1TDP1 | |
| SCHEMBL145855 | 0.74 | ALDH1A1 (0.62) | ALDH1A1CYP3A4TSHRMAPK1TDP1 | |
| SCHEMBL460486 | 0.72 | CA1 (0.43) | ALDH1A1TSHRTDP1CYP1A1CYP1B1 | |
| SCHEMBL29587173 | 0.71 | ALDH1A1 (0.59) | ALDH1A1CYP3A4TSHRMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062085-B2 | Biaryl diphosphine ligands, intermediates of the same and their use in asymmetric catalysis | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2015-06-23 | — | — | US | disclosed |
| US-20130184479-A1 | BIARYL DIPHOSPHINE LIGANDS, INTERMEDIATES OF THE SAME AND THEIR USE IN ASYMMETRIC CATALYSIS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2013-07-18 | — | — | US | disclosed |
| EP-2614069-A1 | BIARYL DIPHOSPHINE LIGANDS, INTERMEDIATES OF THE SAME AND THEIR USE IN ASYMMETRIC CATALYSIS | Kanata Chemical Technologies Inc. (CA) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012031358-A1 | BIARYL DIPHOSPHINE LIGANDS, INTERMEDIATES OF THE SAME AND THEIR USE IN ASYMMETRIC CATALYSIS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184479-A1 | BIARYL DIPHOSPHINE LIGANDS, INTERMEDIATES OF THE SAME AND THEIR USE IN ASYMMETRIC CATALYSIS | AGPS, COASY, BLVRB | ALDH1A1 1187/4885CYP3A4 121/4885TSHR 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.